The FDA Wednesday approved Arexvy, the first vaccine for Respiratory Syncytial Virus for people 60 or older. RSV is a highly contagious respiratory tract disease and can be life-threatening.
May 3 The FDA on Wednesday approved Arexvy, the first approved vaccine for Respiratory Syncytial Virus for people 60 or older.
RSV is a highly contagious respiratory tract disease and can be life-threatening.
GlaxoSmithKline Biologicals, maker of the vaccine, said in a statement Wednesday that the U.S. launch of Arexvy is planned for the 2023/2024 RSV season.
«Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year,» said GSK Chief Scientific Officer Tony Wood in a statement. «Our focus now is to ensure eligible older adults in the U.S. can access the vaccine as quickly as possible and to progress regulatory review in other countries.»
The FDA said the approval is an important public health achievement.
«Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,» said the FDA’s Peter Marks in a statement.
